title: Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease.
abstract: To clarify the relationship between hepatitis C virus (HCV) genotypes and liver disease, we typed HCV genomes in the sera of 151 blood donors, 180 patients with type C chronic liver disease (CLD), and 30 haemophiliacs residing in Hiroshima, Japan. All of the subjects were positive for anti-HCV and HCV-RNA, and were examined for seroreactivity to HCV-specific antigens. The HCV genotypes were determined by polymerase chain reaction (PCR) with type-specific primers deduced from the putative core region of the HCV genome. Significantly more (P < 0.001) type III HCV was found in the samples from the CLD patients (80%) than in those from the blood donors (55%). Significantly more (P < 0.001) type III HCV was found in the samples from the blood donors (29.1%) than in those from the CLD patients (11.7%). There was no significant difference in the distribution of the HCV types among the patients with chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma. A four-antigen recombinant immunoblot assay (RIBA-2) assay was used to compare the serum samples for their reactivity to a range of structural and nonstructural peptides specific for HCV (5-1-1, C100-3, C33c, and C22-3). The frequency of seropositivity to 5-1-1 and C100-3 was significantly higher (P < 0.001) in type II HCV-infected blood donors than in type III HCV-infected donors (68.2% and 65.9% vs. 4.5% and 22.7%, respectively). Among the type III HCV-infected individuals, the CLD patients had a significantly higher (P < 0.01) frequency of seropositivity to 5-1-1 than the blood donors (33.3% vs. 4.5%).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Institute of Clinical Research, Kure National Hospital, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ichimura
authors.forename: I
authors.initials: I
authors.lastname: Tamura
authors.forename: O
authors.initials: O
authors.lastname: Kurimura
authors.forename: T
authors.initials: T
authors.lastname: Koda
authors.forename: M
authors.initials: M
authors.lastname: Mizui
authors.forename: H
authors.initials: H
authors.lastname: Tsuchie
authors.forename: T
authors.initials: T
authors.lastname: Kurimura
mesh_terms: D000328:Adult; D000368:Aged; D000956:Antigens, Viral; D001483:Base Sequence; D017931:DNA Primers / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D016679:Genome, Viral; D005838:Genotype; D006467:Hemophilia A / Q000276:immunology / Q000821:virology; D016174:Hepacivirus / Q000235:genetics* / Q000276:immunology / Q000472:pathogenicity; D006508:Hepatitis Antibodies / Q000097:blood; D006526:Hepatitis C / Q000209:etiology / Q000276:immunology / Q000821:virology*; D018937:Hepatitis C Antibodies; D018936:Hepatitis C Antigens; D006801:Humans; D015151:Immunoblotting; D008107:Liver Diseases / Q000276:immunology / Q000821:virology; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data
chemical_list: D000956:Antigens, Viral; D017931:DNA Primers; D004279:DNA, Viral; D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D018936:Hepatitis C Antigens